- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm | 390 | PR Newswire | UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating... ► Artikel lesen | |
| Mi | Orexo AB reports Q1 results | 1 | Seeking Alpha | ||
| Mi | Orexo Q1 2024 Interim Report | 229 | PR Newswire | UPPSALA, Sweden, May 8, 2024 /PRNewswire/ --
Starting 2024 with a positive EBITDA
Q1 2024 highlights
Total net revenues of SEK 139.3 m (158.8)EBITDA of SEK 15.9 m (-41.1)Net... ► Artikel lesen | |
| 26.04. | Report from Orexo AB's annual general meeting, 26 April 2024 | 182 | PR Newswire | UPPSALA, Sweden, April 26, 2024 /PRNewswire/ --
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance... ► Artikel lesen | |
| 17.04. | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | 201 | PR Newswire | UPPSALA, Sweden, April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another... ► Artikel lesen | |
| 02.04. | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled | 210 | PR Newswire | UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the... ► Artikel lesen | |
| 28.03. | Orexo publishes the Annual and Sustainability Report for 2023 | 261 | PR Newswire | UPPSALA, Sweden, March 28, 2024 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report... ► Artikel lesen | |
| 22.03. | Orexo AB: Notice of Annual General Meeting of Orexo | 250 | PR Newswire | UPPSALA, Sweden, March 22, 2024 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held... ► Artikel lesen | |
| 13.03. | Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds | 361 | PR Newswire | UPPSALA, Sweden, March 13, 2024 /PRNewswire/ -- Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued new senior secured callable floating rate social... ► Artikel lesen | |
| 08.03. | Orexo strengthens its sustainability work by establishing a social financing framework | 210 | PR Newswire | UPPSALA, Sweden, March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ('Orexo' or the 'Company') (STO: ORX) (OTCQX: ORXOY) today announces that the Company has established a social financing framework... ► Artikel lesen | |
| 08.03. | Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds | 243 | PR Newswire | UPPSALA, Sweden, March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier and Carnegie Investment Bank as arrangers... ► Artikel lesen | |
| 12.02. | Orexo AB Advances Exploratory Feasibility Study with Sobi | 1 | Contract Pharma | ||
| 12.02. | Orexo and Sobi agree to advance feasibility study with AmorphOX | 284 | PR Newswire | Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company's world-class drug delivery platform, AmorphOX®The feasibility study confirmed that the... ► Artikel lesen | |
| 08.02. | Orexo Interim Report Q4 2023, incl. Full Year Report | 438 | PR Newswire | UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024
Q4 2023 highlights
Total net revenues of SEK 166.0 m (156.1)EBITDA of SEK 12.4... ► Artikel lesen | |
| 06.02. | Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC | 168 | PR Newswire | OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company's proprietary drug delivery platform, AmorphOX®The... ► Artikel lesen | |
| 28.11.23 | FDA accepts Orexo's NDA for opioid overdose medication | 4 | Pharmaceutical Technology | ||
| 28.11.23 | Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose | 308 | PR Newswire | OX124 is based on Orexo's world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanylSynthetic opioids are... ► Artikel lesen | |
| 02.11.23 | Orexo Q3 2023 Interim Report | 377 | PR Newswire | Big step forward in launching OX124 in the US
UPPSALA, Sweden, Nov. 2, 2023 /PRNewswire/ --
Q3 2023 highlights› Total net revenues of SEK 156.1 m (161.0)› EBITDA of SEK... ► Artikel lesen | |
| 27.10.23 | Orexo announces changes in the company's Board of Directors | 331 | PR Newswire | UPPSALA, Sweden, Oct. 27, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety... ► Artikel lesen | |
| 26.10.23 | Orexo's Nomination Committee for the Annual General Meeting 2024 | 408 | PR Newswire | UPPSALA, Sweden, Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26, a Nomination Committee has been appointed. The shareholders... ► Artikel lesen |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 6,015 | 0,00 % | Nach Aurora, Canopy und Tilray: Diese Cannabis-Aktie ist superheiß | Die Cannabis-Branche hat zuletzt neue Impulse vom Rescheduling in den USA sowie die Freigabe in Deutschland erhalten. Vor diesem Hintergrund ging es für zahlreiche Cannabis-Player teils zweistellig... ► Artikel lesen | |
| ABBVIE | 149,26 | +0,04 % | AbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In Adults | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) announced Wednesday that Health Canada approved Qulipta, also known as atogepant, for preventing migraines in adults with at least four migraine days... ► Artikel lesen | |
| TILRAY BRANDS | 1,806 | +0,50 % | Tilray Brands stock price analysis: TLRY is extremely risky, avoid | ||
| TEVA | 15,050 | -0,33 % | Teva And Medincell Say Phase 3 SOLARIS Study In Schizophrenia Met Primary Goal | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Medincell Wednesday said the Phase 3 SOLARIS study evaluating TEV-'749 in adult... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 41,745 | +0,11 % | Bristol-Myers Squibb Aktienanalyse: -46% Crash vom Allzeithoch und 5 % Dividende als Einstiegschance nutzen? | Die Wachstumsraten von Bristol-Myers Squibb überzeugten im ersten Quartal 2024, jedoch sieht sich das Unternehmen einer Patentklippe konfrontiert. Die Bewertung der Aktie ist attraktiv und die Dividende... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 392,30 | -0,08 % | Vertex Pharmaceuticals Inc. Q1 Profit Increases, beats estimates | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for its first quarter that increased from last year and beat the Street estimates.The company's bottom... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 11,155 | -0,54 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy | - DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months - - DURAVYU continues to demonstrate favorable safety and tolerability profile with... ► Artikel lesen | |
| BAUSCH HEALTH | 6,410 | +0,28 % | Bausch Health Companies Inc: Bausch Health's Salix adds Young as Xifaxan ambassador | ||
| EDWARDS LIFESCIENCES | 81,34 | +1,06 % | Edwards Lifesciences Corporation: Edwards stellt Herzklappenmodell SAPIEN 3 Ultra RESILIA mit Technologie für verbesserte Haltbarkeit in Europa vor | Edwards Lifesciences meldete heute den europäischen Marktauftritt des Herzklappenmodells SAPIEN 3 Ultra RESILIA, der einzigen Transkatheter-Aortenklappe, die die unternehmenseigene bahnbrechende RESILIA-Gewebetechnologie... ► Artikel lesen | |
| BIONANO GENOMICS | 0,956 | -2,75 % | Bionano stock climbs 7% in wake of Q1 report, software upgrades | ||
| ASTRIA THERAPEUTICS | 9,500 | +4,97 % | Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| AMARIN | 0,810 | +1,89 % | Amarin Corporation plc: Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference | ||
| OPKO HEALTH | 1,154 | -2,52 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results | MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights... ► Artikel lesen | |
| JAGUAR HEALTH | 0,270 | -0,22 % | Jaguar Health, Inc.: Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease and Short Bowel Syndrome in Europe | Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May... ► Artikel lesen | |
| ENDO INTERNATIONAL | 0,010 | 0,00 % | Endo, Inc.: Endo Announces New Peyronie's Disease Data Presented at the American Urological Association Annual Meeting | MALVERN, Pa., May 7, 2024 /PRNewswire/ -- Endo, Inc. announced today that three new presentations related to Peyronie's disease and XIAFLEX® (collagenase clostridium histolyticum) were shared... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
